SCHEMBL1298471

SCHEMBL1298471

O=c1[nH]cc(Cl)c2nc(N3CCC(O)CC3)nc(Nc3cccc(C(F)(F)F)c3)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.73
IDH2 P48735 13/20 0.60
TACR2 P21452 1/20 0.45
MAPT P10636 1/20 0.45
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
APP P05067 1/20 0.44
CTSC P53634 1/20 0.43
MAP3K7 O43318 1/20 0.42
CSF1R P07333 1/20 0.42
PIM1 P11309 1/20 0.42
MAPK3 P27361 1/20 0.42
MAPK1 P28482 1/20 0.42
SYK P43405 1/20 0.42
BLK P51451 1/20 0.42
RIPK4 P57078 1/20 0.42
CSNK2A1 P68400 1/20 0.42
KCNH2 Q12809 1/20 0.42
MAP2K5 Q13163 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1299513 0.90 LRRK2 (0.73) LRRK2IDH2TACR2MAPTMEN1
SCHEMBL12655402 0.86 LRRK2 (0.54) LRRK2IDH2MAPTALDH1A1SYK
SCHEMBL1298107 0.85 LRRK2 (1.00) LRRK2IDH2TACR2MAPTMEN1
SCHEMBL1298643 0.81 LRRK2 (0.91) LRRK2IDH2MAP3K7CSF1RPIM1
SCHEMBL1298646 0.81 LRRK2 (0.91) LRRK2IDH2MAP3K7CSF1RPIM1
SCHEMBL1299016 0.81 LRRK2 (0.91) LRRK2IDH2MAP3K7CSF1RPIM1
SCHEMBL1298753 0.79 LRRK2 (0.53) LRRK2IDH2TACR2MAPTMEN1
SCHEMBL12104063 0.79 LRRK2 (0.58) LRRK2IDH2CTSCMAP3K7CSF1R
SCHEMBL1298712 0.78 LRRK2 (0.57) LRRK2IDH2TACR2SYK
Hydrochloric Acid SCHEMBL1298363 0.78 LRRK2 (0.57) LRRK2IDH2CTSCMAP3K7CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404677-B2 Kinase inhibitors GENOSCO (US) 2013-03-26 US claimed
EP-2493313-A1 KINASE INHIBITORS Genosco (US) 2012-09-05 EP claimed
US-20110269739-A1 KINASE INHIBITORS OSCOTEC, INC. (KR) 2011-11-03 US claimed
WO-2011053861-A1 KINASE INHIBITORS GENOSCO (US) 2011-05-05 WO claimed
US-8404677-B2 Kinase inhibitors GENOSCO (US) 2013-03-26 US disclosed
US-8404677-B2 Kinase inhibitors GENOSCO (US) 2013-03-26 US disclosed
US-20110269739-A1 KINASE INHIBITORS OSCOTEC, INC. (KR) 2011-11-03 US disclosed
US-20110269739-A1 KINASE INHIBITORS OSCOTEC, INC. (KR) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269739-A1 KINASE INHIBITORS JAK1, LCK, MAP3K20 LRRK2 436/4885IDH2 1117/4885TACR2 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.